Stephens Investment Management Group LLC Cuts Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND
Stephens Investment Management Group LLC decreased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 9.6% in the fourth quarter, though it remains its 16th largest holding. Despite positive analyst sentiment and a "Moderate Buy" consensus rating, the company reported mixed quarterly results with EPS and revenue missing estimates. Insider selling by Stephen L. Sabba and Andrew Reardon also occurred within the last 90 days.
UBS Group AG Purchases 31,081 Shares of Ligand Pharmaceuticals Incorporated $LGND
UBS Group AG significantly increased its stake in Ligand Pharmaceuticals, purchasing 31,081 additional shares in the fourth quarter, bringing its total holding to 143,067 shares valued at approximately $27.05 million. This comes amidst mixed analyst sentiment, with several firms raising price targets and maintaining buy ratings despite the company missing Q1 EPS and revenue estimates, though revenue still grew year-over-year. Insider selling has also been noted, with the CFO and a director reducing their holdings.
Ligand to Participate in May Investor Conferences
Ligand Pharmaceuticals announced its senior management team will participate in several investor conferences throughout May 2026, including the H.C. Wainwright Royalty Company Conference, Bank of America Healthcare Conference, CJS Securities Spring 1x1 Conference, H.C. Wainwright BioConnect Investor Conference, RBC Capital Markets Global Healthcare Conference, Craig-Hallum Institutional Investor Conference, and Benchmark Healthcare House Call Conference. During these events, management will engage in fireside chats and host one-on-one meetings with investors and attendees. Ligand, a leading royalty aggregator, funds biopharmaceutical development programs in exchange for economic interests, boasting a diverse portfolio of over 100 assets.
Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating the sales of XOMA Royalty Corporation, RE/MAX Holdings, Inc., and KalVista Pharmaceuticals, Inc. The firm is examining potential violations of federal securities laws and breaches of fiduciary duties to shareholders, particularly regarding whether insiders unfairly benefit from these deals. Shareholders are encouraged to contact the firm to discuss their rights and options.
Vanguard Capital Management files Schedule 13G on Ligand (LGND) showing 5% stake
Vanguard Capital Management has filed a Schedule 13G on Ligand Pharmaceuticals Inc. (LGND), reporting a beneficial ownership of 997,637 shares, which represents a 5% stake in the company's common stock as of March 31, 2026. The filing indicates Vanguard possesses sole dispositive power over all these shares and sole voting power over 149,548 shares. This disclosure provides transparency regarding Vanguard's significant investment in Ligand.
Vanguard reports 5.56% stake in Ligand Pharmaceuticals (NASDAQ: LGND)
Vanguard Portfolio Management has reported a 5.56% beneficial ownership stake in Ligand Pharmaceuticals Inc. (NASDAQ: LGND), holding 1,109,154 shares. The Schedule 13G filing indicates sole voting power over 8,887 shares and sole dispositive power over all 1,109,154 shares. This disclosure, signed by Ashley Grim on May 1, 2026, highlights Vanguard's significant but passive investment in the biotechnology company.
[8-K] LIGAND PHARMACEUTICALS INC Reports Material Event
Ligand Pharmaceuticals Inc. (LGND) filed an 8-K report announcing the termination of the TR-Beta Program under its Master License Agreement with Viking Therapeutics, Inc., effective May 4, 2026. Ligand asserts that Viking materially breached its obligation to use commercially reasonable efforts for the program's development and commercialization. Viking disputes this termination, while Ligand intends to vigorously enforce its rights.
Ligand Pharmaceuticals to Acquire XOMA Royalty for $39 Per Share Plus CVRs
Ligand Pharmaceuticals has entered into a definitive merger agreement to acquire XOMA Royalty for $39.00 per share in cash, along with contingent value rights (CVRs) tied to a CVR Trust. The deal is contingent on XOMA Royalty stockholder approval, HSR clearance, and a holding company reorganization and CVR spin. Ligand has also secured voting and support agreements from holders representing approximately 47% of XOMA Royalty's common shares to facilitate the transaction.
B. Metzler seel. Sohn & Co. AG Invests $1.30 Million in Ligand Pharmaceuticals Incorporated $LGND
B. Metzler seel. Sohn & Co. AG has invested $1.30 million in Ligand Pharmaceuticals (NASDAQ:LGND) by purchasing 6,879 shares in Q4, bringing institutional ownership to approximately 91.28%. Despite this, company insiders, including the CFO and a director, have recently sold shares totaling about $6.39 million. Ligand Pharmaceuticals reported strong quarterly earnings, beating estimates with $2.02 EPS and $59.67 million in revenue, and has issued a positive FY2026 EPS guidance of $8.00–$9.00.
Ligand (Nasdaq: LGND) to acquire XOMA Royalty in $739M, EPS‑accretive deal
Ligand Pharmaceuticals announced its agreement to acquire XOMA Royalty Corporation for $739 million in cash, equating to $39.00 per share plus a contingent value right tied to Janssen litigation proceeds. This acquisition will significantly expand Ligand's biopharma royalty portfolio by adding seven commercial products and over 100 development-stage assets. Ligand expects the deal to be immediately accretive, raising its 2026 adjusted EPS guidance to $8.50–$9.50 and projecting an additional $1.50 per share to adjusted EPS in 2027.
Impax Asset Management Group plc Sells 35,000 Shares of Ligand Pharmaceuticals Incorporated $LGND
Impax Asset Management Group plc reduced its stake in Ligand Pharmaceuticals Incorporated by 17.5%, selling 35,000 shares and now holding 165,208 shares valued at approximately $31.24 million. Despite this sale, Ligand Pharmaceuticals reported strong quarterly results with EPS of $2.02 and revenue of $59.67 million, exceeding analyst expectations, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $247.29. Insider selling was also noted, with executives selling shares totaling over $1.6 million, while institutional investors collectively own 91.28% of the company's stock.
Assetmark Inc. Raises Holdings in Ligand Pharmaceuticals Incorporated $LGND
Assetmark Inc. significantly increased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 4,933.3%, now owning 6,191 shares valued at approximately $1.17 million. Analysts maintain a "Moderate Buy" consensus with a price target of $247.29, following strong quarterly earnings where Ligand reported $2.02 EPS (beating estimates by $0.56) and revenue of $59.67 million, up 39.5% year-over-year. The company also provided a positive FY2026 EPS guidance of $8.00–$9.00.
Ligand (NASDAQ: LGND) posts strong 2025 growth and seeks approval for expanded equity plan
Ligand Pharmaceuticals (LGND) is seeking stockholder approval for an expanded equity plan at its June 5, 2026, annual meeting, following a strong financial performance in 2025. The company reported a 48% increase in royalty revenue and a 42% rise in adjusted EPS, driven by its royalty-focused biopharmaceutical model and successful partner product launches. The proposed changes to the 2002 Stock Incentive Plan include increasing the share reserve by 600,000 shares, removing the fungible pool formula, and updating director compensation limits, aimed at maintaining competitive employee and director incentives.
LGND Financials: Revenue Breakdown, Margins & Competitor Comparison
The article analyzes Ligand Pharmaceuticals Inc (LGND) financials, highlighting its revenue breakdown, profitability margins, and competitive position. Kyprolis is LGND's largest revenue contributor, accounting for 18.5% of total sales. The company demonstrates strong profitability with an 81.42% gross margin and a 75.06% net margin, outperforming competitors like AMRX in efficiency.
Aberdeen Group plc Lowers Stock Position in Ligand Pharmaceuticals Incorporated $LGND
Aberdeen Group plc has reduced its stake in Ligand Pharmaceuticals Incorporated by 37.1% during the fourth quarter, selling over 70,000 shares. Despite this reduction and recent insider selling, Ligand Pharmaceuticals reported strong quarterly results, beating EPS and revenue estimates, and analysts maintain a "Moderate Buy" rating with a target price of $245.86. Institutional investors collectively own a significant portion of the company's stock at 91.28%.
Ligand (NASDAQ: LGND) director exercises options, sells 2,161 common shares
John L. LaMattina, a director at Ligand Pharmaceuticals (NASDAQ: LGND), exercised non-qualified stock options for 2,161 shares at $114.15 per share and subsequently sold all those shares for $200.76 per share in an open-market transaction. Following these transactions on March 6, 2026, LaMattina directly holds 30,724 shares of Ligand common stock, with the option position now fully exercised. The net sale amounted to 2,161 shares, valued at $433,842.
LGND Technical Analysis & Stock Price Forecast
This article provides a technical analysis of Ligand Pharmaceuticals Inc (LGND), indicating a "Sell" consensus based on various indicators. It details the stock's performance relative to moving averages, its RSI, MACD readings, and key support and resistance levels. The analysis aggregates 10 technical signals, showing more sell indicators than buy indicators as of April 2, 2026.
Ligand Pharma CLO Sells $1.03M in Stock | Transaction Details & Company Background - News and Statistics
Ligand Pharmaceuticals Inc.'s Chief Legal Officer, Andrew Reardon, sold approximately $1.03 million in company stock after exercising options for 5,000 shares. This transaction reduced his direct holdings by nearly 12%, though he still retains substantial unexercised employee stock options. The sale occurred at a weighted average price of $206.35 per share, following Ligand's strong one-year stock performance exceeding 80%.
Vanguard (LGND) reports 0 shares after internal realignment (03/27/2026)
The Vanguard Group filed an amended Schedule 13G/A report for Ligand Pharmaceuticals Inc. (LGND), stating it now beneficially owns 0 shares and 0% of the common stock. This change is due to an internal realignment within Vanguard, where certain subsidiaries will now report their holdings separately, as per SEC Release No. 34-39538. This filing reflects an administrative change rather than a sale or purchase of stock.
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team
Ligand Pharmaceuticals announced the appointment of Peter Renehan, MD, and Lee Brown as Vice Presidents of Investments and Business Development, expanding its team. Lauren Hay is also transitioning to Vice President of Portfolio Strategy and Investments. These changes aim to strengthen Ligand's strategic growth, capitalize on new investment opportunities, and enhance long-term value creation by focusing on royalty financing and optimizing existing portfolio assets.
Ligand Pharmaceuticals Unveils Two New VPs of Investments, Business Development
Ligand Pharmaceuticals has appointed Peter Renehan, MD, and Lee Brown as new Vice Presidents of Investments and Business Development, both reporting to SVP Paul Hadden. Their role will focus on sourcing and executing royalty financing opportunities. Additionally, Lauren Hay has been promoted to Vice President of Portfolio Strategy and Investments, overseeing the optimization and management of Ligand's existing portfolio assets.
Ligand Pharmaceuticals (LGND) director sells 1,000 shares, keeps stake
Ligand Pharmaceuticals director Stephen L. Sabba sold 1,000 shares of common stock on March 23, 2026, for an average price of $207.8727 per share. Following this transaction, Sabba directly holds 32,793 shares, which includes 1,209 restricted shares previously reported and expected to vest within six months. The sale was documented in a Form 4 SEC filing, indicating a net sale of approximately $208,000.
Clark Capital Management Group Inc. Acquires 11,858 Shares of Ligand Pharmaceuticals Incorporated $LGND
Clark Capital Management Group Inc. increased its stake in Ligand Pharmaceuticals Incorporated by 16.7% in the third quarter, purchasing an additional 11,858 shares. This acquisition brings their total holdings to 82,991 shares, valued at $14.7 million. Other institutional investors also significantly boosted their positions in Ligand Pharmaceuticals, while company insiders recently sold shares totaling millions.
LIGAND PHARMACEUTICALS CFO Sells Shares
LIGAND PHARMACEUTICALS' CFO, Espinoza Octavio, sold 3,057 shares of common stock for $687,825 on March 11, 2026. This transaction was part of a pre-arranged trading plan, leaving him with 21,010 direct shares in the company. The sale details were disclosed in an SEC Form 4 filing on March 13, 2026.
Russell Investments Group Ltd. Sells 9,403 Shares of Ligand Pharmaceuticals Incorporated $LGND
Russell Investments Group Ltd. has reduced its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 6.5% during the third quarter, selling 9,403 shares and now holding 136,130 shares valued at $24.1 million. Despite insider selling, analysts maintain a "Moderate Buy" rating with an average target price of $245, following the company beating earnings expectations and providing strong FY2026 guidance. Institutional investors collectively own over 91% of Ligand Pharmaceuticals.
Bofa Global Research announced that it has initiated coverage of Ligand Pharmaceuticals Inc. for the first time, assigning it a "Buy" rating.
Bofa Global Research has initiated coverage of Ligand Pharmaceuticals Inc. with a "Buy" rating and set a target stock price of $244 for the biopharmaceutical company. The article cites this as new coverage for Ligand Pharmaceuticals.
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says
Bank of America has initiated coverage of Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy rating and a $244 price target, highlighting the company's royalty-focused business model and diversified portfolio. Ligand's strategy of providing capital and technology to drug developers in exchange for royalties allows it to generate high-margin returns with reduced risk in the biopharma sector. The company's strong EPS growth, disciplined deal-making, and technology platforms like Captisol are key drivers for its projected 23% CAGR in royalty receipts through 2030.
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says
Bank of America has initiated coverage of Ligand Pharmaceuticals Inc (NASDAQ:LGND) with a Buy rating and a $244 price target, highlighting the company's royalty-focused business model and diversified portfolio. The firm believes Ligand's strategy of providing capital and technology in exchange for royalties allows it to deliver diversified, high-margin returns and continued EPS growth for investors seeking biopharma exposure with lower risk. The report also pointed to Ligand's strong investment team and its Captisol drug formulation technology as additional drivers for future growth and potential multiple expansion.
LIGAND PHARMACEUTICALS INC SEC 10-K Report
Ligand Pharmaceuticals Inc. has released its 2025 10-K report, highlighting significant financial growth with total revenue of $268.1 million and a net income of $124.5 million. The biopharmaceutical royalty aggregator operates with a lean model, focusing on acquiring and managing royalty interests in various biopharmaceutical products, including key assets like Kyprolis and Filspari. While demonstrating robust performance and strategic advancements like the Pelthos Transaction and new financing, the company also acknowledges operational, intellectual property, regulatory, and financial risks inherent in its business model.
Vanguard Group Inc. Has $367.79 Million Stake in Ligand Pharmaceuticals Incorporated $LGND
Vanguard Group Inc. decreased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 0.6% in the third quarter, yet still holds 10.59% of the company, valued at $367.79 million. Ligand Pharmaceuticals recently exceeded Q4 earnings and revenue expectations and provided strong FY2026 adjusted EPS guidance, projecting substantial growth in royalty revenue through 2030. Despite insider selling and some investor uncertainty regarding revenue guidance, analysts largely maintain a "Moderate Buy" rating for the stock.
Ligand Pharmaceuticals (NasdaqGM:LGND) Stock Price
This article provides an analysis of Ligand Pharmaceuticals (NasdaqGM:LGND), highlighting its stock performance, fair value, and financial metrics. It details the company's diverse royalty partnerships and asset-light acquisitions as key drivers for strengthening its global healthcare reach, boosting recurring revenue, and supporting future earnings. The report also includes recent news, key financial details, and comparisons with competitors.
Aberdeen Group plc Has $33.61 Million Stock Position in Ligand Pharmaceuticals Incorporated $LGND
Aberdeen Group plc reduced its stake in Ligand Pharmaceuticals by 17.2% in Q3, owning 189,748 shares valued at $33.61 million. Institutional investors collectively own 91.28% of the stock, while company insiders have sold 3,205 shares worth $611,192 in the last quarter. Analysts maintain a "Moderate Buy" consensus with an average price target of $239.33.
Ligand Pharmaceuticals Announces Fourth Quarter and Full Year 2025 Financial Results Call Scheduled for February 26, 2026
Ligand Pharmaceuticals (LGND) will release its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss the results and provide a business update. The biopharmaceutical company focuses on supporting the development of medicines through financing and licensing technologies, partnering with leading pharmaceutical companies, and leveraging its Captisol® and NITRICIL™ platform technologies. The article also provides detailed information on insider trading activity, institutional holdings, analyst ratings, and price targets for LGND.
Ligand Pharmaceuticals Announces Fourth Quarter and Full Year 2025 Financial Results Call Scheduled for February 26, 2026
Ligand Pharmaceuticals announced it will release its Q4 and full-year 2025 financial results on February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss the results and provide a business update. The biopharmaceutical company focuses on supporting the development of high-value medicines through financing and licensing technologies, partnering with leading pharmaceutical companies. The article also provides details on insider trading activity, revenue, hedge fund activity, analyst ratings, and price targets for LGND stock.
Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Ligand Pharmaceuticals Incorporated announced it will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a business update. Ligand is a biopharmaceutical company focused on enabling scientific advancement through financing and licensing technologies for high-value medicines.
Impax Asset Management Group plc Sells 60,000 Shares of Ligand Pharmaceuticals Incorporated $LGND
Impax Asset Management Group plc has reduced its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 23.1%, selling 60,000 shares but still retaining over 200,000 shares valued at approximately $35.5 million. Analyst sentiment for LGND is positive, with a "Moderate Buy" consensus rating and a target price significantly above its current trading price. However, company insiders have been engaged in selling shares, indicating some internal divestment.
Villere ST Denis J & Co. LLC Has $49.59 Million Stock Position in Ligand Pharmaceuticals Incorporated $LGND
Villere ST Denis J & Co. LLC has reduced its stake in Ligand Pharmaceuticals Incorporated by 2.5%, now holding 279,950 shares valued at $49.59 million, representing 1.43% of the company. Despite this reduction, Ligand Pharmaceuticals remains Villere ST Denis J & Co. LLC's second-largest holding, accounting for 4.8% of its portfolio. The biotechnology company has received a "Moderate Buy" consensus rating from analysts, with an average price target of $239.33, and reported strong Q3 earnings with $3.09 EPS and 123% YoY revenue growth.
Stephens Investment Management Group LLC Sells 50,271 Shares of Ligand Pharmaceuticals Incorporated $LGND
Stephens Investment Management Group LLC reduced its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 8.3% in the third quarter, selling over 50,000 shares. Despite this, the firm still holds a significant position worth approximately $98.23 million. Ligand Pharmaceuticals reported strong earnings and revenue, with positive analyst sentiment, maintaining a "Moderate Buy" rating and a consensus price target indicating potential upside.
Ligand Pharmaceuticals Insiders Sell US$2.8m Of Stock, Possibly Signalling Caution
Over the past year, insiders at Ligand Pharmaceuticals (NASDAQ:LGND) sold US$2.8 million worth of stock, while purchasing US$1.2 million. This significant selling, particularly by Independent Director Jason Aryeh at a price below the current valuation and recent sales by CFO Octavio Espinoza, suggests a cautious outlook from insiders. Despite insiders holding 2.1% of the company, the net selling activities raise questions for potential investors.
Ligand Pharmaceuticals Incorporated $LGND Position Trimmed by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC reduced its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 12.7% in Q3, now owning 294,490 shares valued at $52.17 million. Despite this trim, LGND remains its third-largest position, representing 2.8% of its investment portfolio. Ligand Pharmaceuticals reported strong earnings with an EPS of $3.09 and revenue of $86.89 million for the quarter, exceeding analyst expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Moderate Buy" by Analysts
Ligand Pharmaceuticals (NASDAQ:LGND) has received a "Moderate Buy" consensus rating from analysts, with an average 1-year price target of approximately $239.33, following several raised price objectives. The company reported strong quarterly earnings, beating expectations with an EPS of $3.09 and revenue up 123% year-over-year, and has set optimistic FY2025 guidance. Insider activity shows recent stock sales by the CFO and a director, while institutional investors hold a significant majority of the shares.
Analysts’ Top Healthcare Picks: Ligand Pharma (LGND), MiMedx Group (MDXG)
This article highlights bullish sentiments from financial analysts on several healthcare stocks. Ligand Pharma (LGND) received a Strong Buy rating with a significant upside, supported by analysts from Craig-Hallum and Citi. MiMedx Group (MDXG) also earned a Strong Buy consensus, with a substantial potential upside, and was reaffirmed by Craig-Hallum.
Ligand Pharmaceuticals (NASDAQ: LGND) outlines Athira investment update and disclosure channels
Ligand Pharmaceuticals (NASDAQ: LGND) has filed an 8-K outlining its communication channels for material disclosures, including information about its private placement investment in Athira Pharma, Inc. The company encourages investors to follow its SEC filings, investor relations website, press releases, public calls, webcasts, and social media accounts (@Ligand_LGND on X and LinkedIn) for important updates. This filing emphasizes transparency and compliance with Regulation FD.
LGND: 2025 Analyst Day
Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its 2025 analyst day, providing a positive outlook for 2026 with revenue guidance of $245-$285 million and EPS of $8.00-$9.00, driven by royalty revenues from Filspari, Ohtuvayre, and Zelsuvmi. The company also raised its five-year compound annual growth rate (CAGR) outlook to 23%, primarily due to existing commercial programs. Catalysts for future growth include potential new indications for Filspari and Qarziba, along with expanded investment capacity.
Ligand Pharmaceuticals Stock (LGND) Opinions on 2025 Investor Day and 2026 Guidance
Ligand Pharmaceuticals' 2025 Investor Day in New York City generated discussion on X regarding its updated 2026 revenue guidance, projected between $245 million and $285 million, with a focus on royalty portfolio growth and strategic partnerships. The stock has seen a 57.96% increase over the past year, trading at $195.56, though some investors remain cautious. Insider trading shows 29 sales in the past 6 months, and institutional investors have largely increased their positions.
Ligand Pharmaceuticals Stock (LGND) Opinions on 2025 Investor Day and 2026 Guidance
Ligand Pharmaceuticals (LGND) held its 2025 Investor Day, sparking discussions on X about its updated 2026 revenue guidance of $245 million to $285 million and focus on royalty portfolio growth. The stock saw a slight uptick to $195.56, reflecting mixed investor sentiment. Insider trading activity shows 29 sales and no purchases in the last six months, while institutional investors have largely increased their positions.
Ligand Pharmaceuticals Provides 2026 Revenue Guidance of $245 Million to $285 Million with Increased Royalty Revenue Outlook | LGND Stock News
Ligand Pharmaceuticals announced its 2026 revenue guidance, projecting between $245 million and $285 million, a 15% increase in core revenue growth. Royalty revenues are expected to rise 40% to $200-$225 million, driven by key products and supported by $1 billion in deployable capital. The company also anticipates core adjusted earnings per diluted share between $8.00 and $9.00 and foresees a long-term compound annual growth rate of at least 23% in royalty receipts.
Ligand Pharmaceuticals Incorporated $LGND Shares Bought by Legal & General Group Plc
Legal & General Group Plc increased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 15.8% in Q2, acquiring 16,171 additional shares. This brings their total holding to 118,333 shares, valued at approximately $13.45 million. The biotechnology company reported strong quarterly earnings, beating analyst expectations, and has received multiple price target increases from brokerage firms.
Peering Into Ligand Pharmaceuticals Inc's Recent Short Interest
Ligand Pharmaceuticals Inc. (LGND) has seen a 7.23% decrease in its short interest, with 1.11 million shares now sold short, representing 6.8% of available shares. This decline in short interest suggests a potentially more bullish sentiment among investors for the company. Compared to its peers, Ligand Pharmaceuticals Inc. has less short interest on average.
Ligand (NASDAQ: LGND) to join UBS, Stifel, IDEAS conferences; fireside chat Nov 12
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that CEO Todd Davis and CFO Tavo Espinoza will participate in three investor conferences in November 2025. These include one-on-one meetings at the UBS Global Healthcare Conference on November 10, a fireside chat at the Stifel 2025 Healthcare Conference on November 12, and a presentation at the Southwest IDEAS 2025 Investor Conference on November 20. Investors interested in scheduling one-on-one meetings should contact their UBS or Stifel representatives.
